Intellipharmaceutics International Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Isa Odidi MBA,
- Full Time Employees
- 11
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 30 Worcester Road Toronto ON Canada M9W 5X2
- IPO Date
- Oct 26, 2009
- CIK
- 0001474835
- Website
- intellipharmaceutics.com
- Similar Companies
- Business
- Intellipharmaceutics International Inc. (IPCIF) researches, develops, and commercializes novel and generic controlled-release and targeted-release oral solid dosage drugs utilizing its proprietary Hypermatrix technology platform. The company offers products including Focalin XR (dexmethylphenidate hydrochloride extended-release capsules for attention hyperactivity disorder); Keppra XR (levetiracetam extended-release tablets for partial onset seizures in epilepsy patients); Effexor XR (venlafaxine hydrochloride extended-release capsules for depression); Protonix (pantoprazole sodium delayed-release tablets for gastroesophageal reflux disease); Glucophage XR (metformin hydrochloride extended-release tablets for type 2 diabetes); Seroquel XR (quetiapine fumarate extended-release tablets for schizophrenia, bipolar disorder, and major depressive disorders); Lamictal XR (lamotrigine extended-release tablets for epilepsy); Pristiq (desvenlafaxine extended-release tablets for depression); Coreg CR (carvedilol phosphate extended-release capsules for heart failure and hypertension); and Ranexa (ranolazine extended-release tablets for chronic angina), as well as pipeline candidates such as abuse-deterrent oxycodone hydrochloride extended-release tablets (Oxycodone ER) under NDA review with the FDA and Regabatin XR (pregabalin extended-release capsules) for neuropathic pain. Its development pipeline includes ANDA and NDA 505(b)(2) filings targeting neurology, cardiovascular, gastrointestinal, diabetes, and pain management therapeutic areas through abuse-deterrent, long-acting oral drug delivery systems (L-ODDS) and nPODDDS platforms. Founded in 1998 and headquartered at 30 Worcester Road, Toronto, Ontario, Canada, the company generates revenue primarily through licensing agreements with Canadian and U.S. pharmaceutical partners and operates in North American markets. In March 2024, Intellipharmaceutics transferred its listing from the TSX Venture Exchange to NEX, a separate board, and adopted a new rolling stock option plan (reserving 10% of shares) subject to shareholder approval, replacing prior compensation plans amid ongoing efforts to file delayed financial reports following a cease trade order.
Analyzing Nuvo Pharmaceuticals (OTCMKTS:MRVFF) and Intellipharmaceutics International (OTCMKTS:IPCIF)
Reviewing Intellipharmaceutics International (OTCMKTS:IPCIF) & Neoleukin Therapeutics (NASDAQ:NLTX)
Intellipharmaceutics Announces Downgrade to OTC Expert Market
Intellipharmaceutics International Inc. Announces Transfer of Listing to NEX and New Stock Option Plan
Intellipharmaceutics Announces Cease Trade Order
Intellipharmaceutics Announces Its Expected Delay in Filing Annual Audited Financial Statements and Annual Information Form
Intellipharmaceutics International Inc. Announces Stock Option Grant
Intellipharmaceutics International Inc. Receives Conditional Approval to List on the TSX Venture Exchange
Intellipharmaceutics Announces Third Quarter 2023 Results
Intellipharmaceutics Reports Director Election Results
Intellipharmaceutics Announces Closing of CAD$3.85 Million Non-Brokered Private Placement
Intellipharmaceutics Announces First Quarter 2021 Results